Evidence in Primary Prevention of Type 2 Diabetes Mellitus—What It Means for Primary Prevention of Type 2 Diabetes Mellitus Epidemic in Papua New Guinea
Type 2 diabetes is in epidemic proportion in Papua New Guinea. Although
many people are at high-risk of developing diabetes, there is no diabetes
prevention policy and services in Papua New Guinea to address this problem. A
literature search was carried out to assess the available evidence in the
primary prevention of type 2 diabetes mellitus among the population with
pre-diabetes. The result shows that
the primary preventative studies conducted on lifestyle modification and the
use of metformin in prediabetes patients reduced overt type 2 diabetes
mellitus. The application of theevidence in the prevention of the type 2 diabetes
epidemic in Papua New Guinea, driven by a policy is feasible to address the
diabetes epidemic.
References
[1]
World Health Organization. Diabetes Program. https://www.who.int/news-room/fact-sheets/detail/diabetes
[2]
Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004) Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030. Diabetes Care, 27, 1047-1053. https://doi.org/10.2337/diacare.27.5.1047
[3]
Papua New Guinea National Department of Health (2010) Annual Report (Unpublished). Government Printers, Waigani.
[4]
Papua New Guinea National Department of Health (2009) Diabetes Survey (Unpublished). Government Printers, Waigani.
[5]
Pulford, J., Rarau, P., Vengiau, G., Gouda, H., Phuanukoonnon, S. and the Scientific Advisory Board (2015) Non-Communicable Diseases and Associated Risk Factors in the Hiri, Asaro and Karkar Integrated Health and Demographic Surveillance Sites. Papua New Guinea Institute of Medical Research, Goroka. https://www.pngimr.org.pg/wp-content/uploads/2019/05/Report-on-Non-Communicable-diseases-associated-risk-factors-in-the-Hiri-Karkar-and-Asaro-integrated-health-and-demographic-surveillance-sites.pdf
[6]
Division of Internal Medicine, Port Moresby General Hospital (2011) Annual Audit Report (Unpublished).
[7]
Engelgau, M.M., Aubert, R.E., Thompson, T.J. and Herman, W.H. (1995) Screening for NIDDM in Non-Pregnant Adults: A Review of Principles, Screening Tests, and Recommendations. Diabetes Care, 18, 1606-1618. https://doi.org/10.2337/diacare.18.12.1606
[8]
Khunti, K. and Davies, M. (2012) Should We Screen for Type 2 Diabetes: Yes. BMJ, 345, e4514. https://doi.org/10.1136/bmj.e4514
[9]
Goyder, E., Irwig, L. and Payne, N. (2012) Should We Screen for Type 2 Diabetes? No. BMJ, 345, E4516. https://doi.org/10.1136/bmj.e4516
World Health Organization, International Diabetes Federation (2006) Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. A Report of a WHO/IDF Consultation. https://www.who.int/diabetes
[12]
Sartor, G., Schersten, B., Carlstrom, S., et al. (1980) Ten-Year Follow-Up of Subjects with Impaired Glucose Tolerance. Prevention of Diabetes by Tolbutamide and Diet Regulation. Diabetes, 29, 41-49. https://doi.org/10.2337/diabetes.29.1.41
[13]
Eriksson, K.F. and Lindgarde, F. (1998) No Excess 12-Year Mortality in Men with Impaired Glucose Tolerance Who Participated in the Malmo Preventive Trial with Diet and Exercise. Diabetologia, 41, 1010-1016. https://doi.org/10.1007/s001250051024
[14]
Pan, X.R., Li, G.W., Hu, Y.H., Wang, J.X., Yang, W.Y., An, Z.X., et al. (1997) Effects of Diet and Exercise in Preventing NIDDM in People with Impaired Glucose Tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care, 20, 537-544. https://doi.org/10.2337/diacare.20.4.537
[15]
Tuomilehto, J., Lindstrőm, J., Erisson, J.G., Valle, T.T., Hämäläinen, H., Ilanne-Parikka, P., et al. (2001) Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. The New England Journal of Medicine, 344, 1343-1350. https://doi.org/10.1056/NEJM200105033441801
[16]
Knowler, W.C., Connor, E.B., Fowler, S.E., Hamman, R.F., Lachin, J.F., Walker, E.A., et al. (2002) Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. The New England Journal of Medicine, 346, 393-403. https://doi.org/10.1056/NEJMoa012512
[17]
Ramachandran, A., Snehalatha, C., Mary, S., et al. (2006) Indian Diabetes Prevention Program (IDPP). The Indian Diabetes Prevention Program Shows That Lifestyle Modification and Metformin Prevent Type 2 Diabetes in Asian Indian Subjects with Impaired Glucose Tolerance (IDPP-1). Diabetologia, 49, 289-297. https://doi.org/10.1007/s00125-005-0097-z
[18]
Chiasson, J.L., Josse, R.G., Gomis, R., et al. (2002) STOP-NIDDM Trial Research Group: Acarbose for Prevention of Type 2 Diabetes Mellitus: The STOP NIDDM Randomised Trial. The Lancet, 359, 2072-2077. https://doi.org/10.1016/S0140-6736(02)08905-5
[19]
Torgerson, J.S., Hauptman, J., Boldrin, M.N. and Sjostrom, L. (2004) Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A Randomized Study of Orlistat as an Adjunct to Lifestyle Changes for the Prevention of Type 2 Diabetes in Obese Patients. Diabetes Care, 27, 151-161. https://doi.org/10.2337/diacare.27.1.155
[20]
Gerstein, H.C., Yusuf, S., Boxch, J., et al. (2006) DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators: Effect of Rosiglitazone on the Frequency of Diabetes in Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose: A Randomized Controlled Trial. The Lancet, 368, 1096-105. https://doi.org/10.1016/S0140-6736(06)69420-8
[21]
Buchanan, T.A., Xiang, A.H., Peters, R.K., et al. (2002) Preservation of Pancreatic Beta-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women. Diabetes, 51, 2796-2803. https://doi.org/10.2337/diabetes.51.9.2796
[22]
DeFronzo, R.A., Tripathy, D., Schwenke, D.C., Banerji, M., Bray, G.A., Buchanan, T.A., Clement, S.C., Henry, R.R., Hodis, H.N., Kitabchi, A.E. and ACT NOW Study Group (2011) Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. The New England Journal of Medicine, 364, 1104-1115. https://doi.org/10.1056/NEJMoa1010949
[23]
Nathan, D.M., Davidson, M., DeFronzo, R.A., et al. (2007) Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for Care. A Consensus Statement from the American Diabetes Association. Diabetes Care, 30, 753-759. https://doi.org/10.2337/dc07-9920
[24]
Stellefson, M., Dipnarine, K. and Stopka, C. (2013) The Chronic Care Model and Diabetes Management in US Primary Care Settings: A Systematic Review. Preventing Chronic Disease, 10, Article ID: 120180. https://doi.org/10.5888/pcd10.120180
[25]
Ahead of Blue Monday. Global Risk Development. https://www.grouprisk.org.uk/2019/01/18/ahead-of-blue-monday-research-from-grid-less-than-a-fifth-of-employers-proactively-manage-stress-and-mental-health-issues
[26]
WHO Regional Office for Europe (2015) Using Price Policies to Promote Healthier Diets. WHO Regional Office for Europe, Copenhagen.
[27]
Veerman, J.L., Sacks, G., Antonopoulos, N. and Martin, J. (2016) The Impact of a Tax on Sugar-Sweetened Beverages on Health and Health Care Costs: A Modelling Study. PLoS ONE, 11, e0151460. http://journals.plos.org/plosone/article?id=10.1371 https://doi.org/10.1371/journal.pone.0151460
[28]
(2016) Sugary Drinks Tax—The Great Debate. Sugar Nutrition Resource Centre. https://www.sugarnutritionresource.org/news-articles/sugary-drinks-tax-the-great-debate
